KLOW Peptide Dosage: Chart, Frequency, Cycle

What Is in the Prescribed Vial

Any KLOW dosage number is meaningless until you know the concentration behind it, and this is where most of the confusion starts. KLOW is not a single molecule with a fixed strength. It is a name for a four-peptide combination, and different suppliers put different amounts of each peptide in the vial. The prescribed version dispensed through PeRx comes from a 503A compounding pharmacy at 3 mg BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , 10 mg GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide , 3 mg KPV, and 3 mg TB-500 per mL, in a 5 mL vial. Total peptide content in the vial is 95 mg, and more than half of it by weight is GHK-Cu.

That vial arrives in solution. It ships fully reconstituted and ready to use, refrigerated, with insulin syringes and swabs in the box. This one fact removes almost every step the online calculators exist to solve. You are not deciding how much diluent to add or converting milligrams into units based on a concentration you chose. The pharmacy chose it, the label states it, and the prescription tells you how many units to draw. If you want the background on the four components, the BPC-157 guide Read nextBPC-157: Complete Guide to Body Protection CompoundA peptide discovered in a Croatian lab in the early '90s is now one of the most studied healing compounds in regenerative medicine. Here's what the science actually says, where it came from, and what you should know before starting.Read article covers the peptide that anchors the blend and What Is KPV Read nextWhat Is KPV? The Peptide Inside KLOWKPV is three amino acids long, which makes it one of the smallest molecules anyone calls a peptide. It came out of hormone research in the late 1980s, it has a real literature behind it, and almost none of that literature involves humans. Here is what is actually known, why PeRx only supplies it inside a four-peptide blend, and what the July 2026 FDA panel vote did and did not do.Read article covers the one most people have never heard of.

KLOW Dosage Chart

The chart below is the prescribed protocol, laid out so you can see how the single syringe number turns into per-peptide milligrams, weekly totals, and a full course. Every row derives from the same two figures: 20 units on a U-100 insulin syringe equals 0.2 mL, and the concentration is 3/10/3/3 mg per mL.

Two things jump out of the table. One week of KLOW delivers exactly the per-mL contents of the vial, because five doses of 0.2 mL is 1 mL, so whatever the label says per mL is your weekly intake. And a 5 mL vial holds 25 doses while a 6-week course needs 30, so plan on a second vial before you start rather than discovering the gap in week five.

Dose Per Day and Per Week

The daily dose is one injection of 20 units. There is no loading phase, no ramp, and no split dosing. There is no titration schedule of the kind GLP-1 protocols use. Day one and day thirty are the same 20 units.

On an insulin syringe, 20 units is a short pull. On a standard 1 mL U-100 syringe it is one-fifth of the barrel; on a 0.5 mL syringe it is two-fifths; on a 0.3 mL syringe it is two-thirds. Read the printed markings, not the volume by eye. The difference between 20 units and 10 units is a few millimeters, and under-drawing is the most common self-inflicted dosing error we see in the first week. If you have never drawn from a vial before, How to Take Peptides Read nextHow to Take Peptides: Injection, Capsule, or StripMost prescription peptides are injected under the skin, a few are swallowed, and a small category dissolves under the tongue. This is the route-of-administration hub: why the route matters, exactly how a subcutaneous injection works, when each peptide is usually taken, what arrives in a PeRx kit, and a directory of per-peptide injection-site guides.Read article walks through the whole sequence from swab to sharps container.

Frequency and Cycle Length

Frequency is Monday through Friday. Cycle length is 6 weeks on, then 6 weeks off. If there is still a reason to use it after the off period, a new cycle can begin, and the prescription for that new cycle goes through the same review as the first. KLOW is not a peptide you stay on indefinitely, and the prescription says so in plain words: do not use continuously.

The off period is not a suggestion tacked onto the end. Three of the four components, BPC-157, TB-500, and KPV, have no human safety data at any duration, and GHK-Cu is a copper complex with a long history in topical cosmetics but a much shorter one as an injectable. Time off is the mechanism that keeps cumulative exposure bounded while the evidence catches up. Six weeks on, six weeks off caps you at 26 dosing weeks in a year, or 130 injections.

Timing and Placement

Time of day is not specified on the KLOW prescription, and that is deliberate. Nothing in the blend is tied to fasting or to the sleep cycle the way growth hormone secretagogues are. The prescription cares about consistency more than the clock: pick a time you can hit five days a week and keep it. Most patients settle on the morning, mainly because the lightheadedness question is easier to manage before the day starts. Evening works just as well if that is when you are reliably home and sitting down. Weekends are off, and that is the schedule rather than a compromise: Saturday and Sunday you take nothing.

Placement is specified, and it is the instruction that makes KLOW different from most peptides on the catalog. The dose goes subcutaneously, as close to the injury site as possible, in a region with a pinchable fold of fat, never into a tendon, a joint, or muscle. You still rotate within that region each day. The full site map, the injury-to-region matching, and the extremity workarounds are in Where to Inject KLOW Read nextWhere to Inject KLOW: Injury Site and RotationKLOW carries a placement instruction most peptides do not: the dose goes as close to the injury site as possible. Four peptides share one vial, and you still have to rotate. Here is how those two instructions fit together in practice.Read article , and they are worth ten minutes before your first dose.

What the 80 mg Charts Get Wrong

Search for KLOW dosage and almost every result describes an 80 mg vial: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, 10 mg KPV, sold as a powder for what the vendor calls research use. The charts that come with it walk through adding diluent, computing a concentration, and drawing some number of units to land on a target dose. None of that applies to the prescribed vial, for four reasons that are worth spelling out because patients arrive with these numbers in their heads.

The ratio is different. The 80 mg blend runs 5:1:1:1 in favor of GHK-Cu. The prescribed vial runs about 3.3:1:1:1. At any given total dose, the research blend delivers proportionally more copper peptide and less of everything else. A chart built for one ratio cannot describe the other.

The concentration is whatever the buyer made it. With a powder, the milligrams per unit depend entirely on how much diluent went in, which is why those charts spend most of their length on mixing math. The prescribed vial has one concentration, set by the pharmacy and printed on the label. The unit-to-milligram conversion is fixed and already done.

The cycle assumptions are different. Research-blend charts commonly describe a 20 to 30 day run of the vial at a daily dose sized to finish it, and then a repeat. Those numbers come from vial economics, not from a clinical rationale. The prescribed protocol runs 5 days a week for 6 weeks and then stops for 6, which is a mandated rest period the vendor charts do not have.

Nobody reviewed it. A research-use vial has no prescriber, no screening for the conditions that matter with this blend, and no one accountable for what is in it. The prescribed dose at PeRx was proposed by the pharmacy and approved as written by a medical director in July 2026. That does not make it a trial-validated dose, but a physician did review the concentration, the frequency, and the cycle. Where to buy peptides legally Read nextWhere to Buy Peptides Legally in 2026On July 30, 2026 a federal judge sent the owner of one of the largest "research peptide" storefronts in the country to prison for nearly six years. This page is the legality map that case makes urgent: the three lanes peptides are sold through, which one you are standing in when you click "buy," and what each lane legally owes you. Written by a clinic that operates inside the middle lane, including where that lane ends.Read article goes into the three sourcing lanes in detail.

Who Is and Is Not a Candidate

Dosing only matters if the blend is appropriate for you in the first place, and KLOW carries more exclusions than a single-peptide prescription because it carries four peptides. The screening at PeRx asks about each of them before a provider reviews the order.

What the FDA Votes Changed

Three of the four peptides in KLOW went before the FDA Pharmacy Compounding Advisory Committee on July 23, 2026, and each was recommended for the 503A bulks list by a vote of 8 to 6. BPC-157, KPV, and TB-500 all cleared on the same day. The fourth component was not on the agenda. Injectable GHK-Cu is among the five substances deferred to a second meeting scheduled before the end of February 2027. The full tally, peptide by peptide, is in our write-up of the July panel Read nextFDA Panel Backs 6 of 7 Peptides, Rejects DSIPThe FDA's Pharmacy Compounding Advisory Committee finished its two-day meeting on July 24, 2026. By the end, it had voted to recommend six of the seven peptides on the agenda for the 503A compounding list, including BPC-157, TB-500, MOTS-C, Semax, and Epitalon, and against just one, Emideltide (DSIP). Every vote went against the FDA's own scientists. Here is the full tally, what it changes, and what it does not.Read article .

What the Evidence Supports

The 20-unit dose is a pharmacy protocol, not a number pulled from a dose-finding study, because no dose-finding study of KLOW exists. It is worth being specific about what does exist for each component, since it explains why the protocol is conservative and why the cycle has an off period.

BPC-157 has the largest literature of the four, and nearly all of it is rodent work from a single research group in Zagreb. The published reviews describe consistent effects on tendon, ligament, muscle, and gut healing in animals at doses that do not translate cleanly to a human protocol. Controlled human trials with published results are essentially absent. That is the state of the evidence for the best-studied ingredient in the vial.

Seiwerth S, Rucman R, Turkovic B, et al. "BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing." Current Pharmaceutical Design. 2018;24(18):1972-1989. View study

TB-500 is a synthetic fragment of thymosin beta-4. The human data that exists belongs to the full thymosin beta-4 molecule, which has been through early-phase wound-healing trials. Those results are sometimes quoted as evidence for TB-500, and they are not the same thing. The fragment itself has no published human dosing data.

Treadwell T, Kleinman HK, Crockford D, et al. "The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients." Annals of the New York Academy of Sciences. 2012;1270:37-44. View study

KPV has a well-cited mechanism paper showing that the tripeptide enters intestinal cells through the PepT1 transporter and dampens inflammatory signaling in cell culture and in mice, and it has zero published human studies by any route. The FDA review that preceded the July vote searched for human data and reported finding none. GHK-Cu is the outlier: it has decades of cosmetic and wound-dressing research behind it, mostly topical, and a review of its gene-expression effects is the usual citation. Injectable human data at 2 mg per day is not something that review contains.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. View study

Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. View study

KLOW Dosage: Common Questions